Comparison 5. Daily cotrimoxazole (CTXp) versus three doses of sulfadoxine‐pyrimethamine (SP).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.1 Maternal peripheral parasitaemia during pregnancy	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.2 Maternal anaemia during delivery	2	362	Risk Ratio (M‐H, Fixed, 95% CI)	1.58 [0.98, 2.53]
5.3 Placental malaria (histology)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.4 Placental malaria (microscopy or polymerase chain reaction)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.5 Clinical malaria episodes during pregnancy	2	362	Risk Ratio (M‐H, Fixed, 95% CI)	1.38 [0.92, 2.07]
5.6 Maternal haemoglobin level at delivery (in g/dL)	1	250	Mean Difference (IV, Fixed, 95% CI)	Not estimable
5.7 Low birth weight (< 2500 g)	3	392	Risk Ratio (M‐H, Fixed, 95% CI)	1.10 [0.68, 1.80]
5.8 Mean birth weight (in grams)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
5.9 Cord blood parasitaemia (rapid diagnostic test)	1	100	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
5.10 Congenital malaria	1	231	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.43, 1.89]
5.11 Prematurity	3	391	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.54, 1.55]
5.12 SAEs during pregnancy	3	412	Risk Ratio (M‐H, Fixed, 95% CI)	1.83 [1.06, 3.15]
5.13 Spontaneous abortion	3	400	Risk Ratio (M‐H, Fixed, 95% CI)	0.40 [0.06, 2.65]
5.14 Stillbirth	3	400	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.31, 2.87]
5.15 Congenital malformations	2	277	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.06, 15.26]
5.16 Maternal mortality	2	362	Risk Ratio (M‐H, Fixed, 95% CI)	2.95 [0.12, 71.79]
5.17 Neonatal mortality	3	392	Risk Ratio (M‐H, Fixed, 95% CI)	3.79 [0.43, 33.43]
5.18 Infant mortality	1	231	Risk Ratio (M‐H, Fixed, 95% CI)	0.32 [0.01, 7.89]
5.19 Adverse events: rash	1	250	Risk Ratio (M‐H, Fixed, 95% CI)	2.95 [0.31, 28.00]
5.20 Mother‐to‐child transmission of HIV	2	310	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.34, 3.06]